U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509801) titled 'A Study to Evaluate the Safety and Efficacy of NT-88' on March 24.

Brief Summary: A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction

Study Start Date: March 30

Study Type: INTERVENTIONAL

Condition: Heart Failure With Mildly Reduced Ejection Fraction

Intervention: DRUG: Conventional therapeutic drugs

Conventional therapeutic drugs

DRUG: NT-88

Conventional therapeutic drugs+NT-88

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Guangzhou Manjing biomedicine technology co., ltd

Disclaimer: Curated by HT Syndication....